RGT — Argent BioPharma Share Price
Last trade - 00:00- AU$5.27m
- AU$4.60m
- AU$0.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -10054.5% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3 | 4.73 | 3.39 | 0.89 | 0.18 | 24.2 | n/a | -38.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Argent BioPharma Limited is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The Company’s assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The Company’s proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. It focuses on urgent unmet needs in the central nervous system (CNS) and systemic inflammation. Its product pipeline includes CimetrA, CannEpil, CogniCann and others. CannEpil is a refractory epilepsy seizure control treatment. CogniCann is an investigational oral spray developed by the Company to help manage symptoms associated with dementia and Alzheimer’s disease. The Company has a patient base in Australia, the United Kingdom, Brazil, and Ireland.
Directors
- Brett Mitchell CHM
- Roby Zomer CEO
- Amir Polak CTO
- Nativ Segev EDR
- Nicole Godresse OTH
- Sabina Suljakovic OTH
- Rachel Kerr SEC
- David Lim SEC (50)
- Stephen Parker NED (62)
- Evan Hayes NID
- Ross Grant Thomas Walker NID
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- October 21st, 2005
- Public Since
- December 21st, 2006
- No. of Shareholders
- 9,027
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 72,183,153
- Address
- Suite 1, 295 Rokeby Road, SUBIACO, 6008
- Web
- https://argentbiopharma.com/
- Phone
- +61 865552950
- Auditors
- Hall Chadwick
Latest News for RGT
Upcoming Events for RGT
Half Year 2026 Argent Biopharma Ltd Earnings Release
Similar to RGT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:19 UTC, shares in Argent BioPharma are trading at AU$0.07. This share price information is delayed by 15 minutes.
Shares in Argent BioPharma last closed at AU$0.07 and the price had moved by -66.82% over the past 365 days. In terms of relative price strength the Argent BioPharma share price has underperformed the ASX All Ordinaries Index by -67.49% over the past year.
The overall consensus recommendation for Argent BioPharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArgent BioPharma does not currently pay a dividend.
Argent BioPharma does not currently pay a dividend.
Argent BioPharma does not currently pay a dividend.
To buy shares in Argent BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.07, shares in Argent BioPharma had a market capitalisation of AU$5.27m.
Here are the trading details for Argent BioPharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RGT
Based on an overall assessment of its quality, value and momentum Argent BioPharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Argent BioPharma is AU$0.04. That is 45.21% below the last closing price of AU$0.07.
Analysts covering Argent BioPharma currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Argent BioPharma. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -23.33%.
As of the last closing price of AU$0.07, shares in Argent BioPharma were trading -32.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Argent BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Argent BioPharma's management team is headed by:
- Brett Mitchell - CHM
- Roby Zomer - CEO
- Amir Polak - CTO
- Nativ Segev - EDR
- Nicole Godresse - OTH
- Sabina Suljakovic - OTH
- Rachel Kerr - SEC
- David Lim - SEC
- Stephen Parker - NED
- Evan Hayes - NID
- Ross Grant Thomas Walker - NID